Physician profile
William Lipsky
NPI 1407850464
$1,602.38
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $291 · 2021: $565 · 2022: $410.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $492.01 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $218.29 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $107.57 | 2019-2022 | |
| Alcon Vision LLC | $97.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $94.19 | 2019-2021 | |
| Biotissue Holdings INC. | $70.47 | 2019-2021 | |
| Dompe US, INC. | $67.61 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $67.45 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $66.66 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $56.84 | 2019 | |
| Allergan, INC. | $52.32 | 2021 | |
| Shire North American Group INC | $45.57 | 2019 | |
| Sun Pharmaceutical Industries INC. | $35.65 | 2022 | |
| Abbvie INC. | $35.38 | 2019-2022 | |
| Sight Sciences, INC. | $33.80 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $33.02 | 2021 | |
| Rxsight INC | $14.55 | 2022 | |
| Akorn, INC. | $13.65 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$11,625.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lipsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.